Pacific Shuanglin Bio-pharmacy (000403.SZ) received a decision letter on administrative supervision measures from the Shanxi Securities Regulatory Bureau.

Pacific Shuanglin Bio-pharmacy (000403.SZ) issued an announcement, stating that the company recently received a decision from the Shanxi Regulatory Bureau of the China Securities Regulatory Commission (referred to as the "Shanxi Securities Regulatory Bureau") regarding the "Decision on Taking Corrective Measures against Pacific Shuanglin Bio-pharmacy Co., Ltd. (2025]18)" and the "Decision on Issuing Warning Letters to Li Hao, Rong Xiankui, Zhao Yulin, Fu Shaolan, and Yuan Huagang". Upon investigation, the company was found to have the following violations: Firstly, the company's subsidiaries signed supplementary agreements, memorandums, etc. with individual customers and promoters regarding certain sales matters with additional liability obligations clauses. However, the signing of these agreements and commitment arrangements were not included in the company's internal control management system, leading to deficiencies in business and contract control within the company, resulting in inaccurate information disclosure. Secondly, some significant matters of the company were not registered for insider information, and some of the insider information registration files were incomplete. The above actions violated the provisions of Article 6 and Article 12 of the "Guidelines for the Application of Enterprise Internal Control No. 9 - Sales Business" (Finance [2010] No. 11), as well as Article 6(1) and Article 7(1) of the "Guidelines for the Regulation of Listed Companies No. 5 - Management System for Registration of Insider Information Informants in Listed Companies" (CSRC Announcement [2022] No. 17). In accordance with Article 52 of the "Regulations on the Disclosure of Information by Listed Companies" (CSRC Order No. 182), Article 21 of the "Rules for On-site Inspection of Listed Companies" (CSRC Announcement [2022] No. 21), and Article 16(3) of the "Guidelines for the Regulation of Listed Companies No. 5 - Management System for Registration of Insider Information Informants", the Shanxi Securities Regulatory Bureau has decided to take supervisory measures requiring the company to amend its actions and record them in the securities and futures market integrity file.